TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
RALEIGH, N.C., April 15, 2016 -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its first quarter 2016 results after the market closes on Wednesday, April 27, 2016. The Company will also host a conference call on Thursday, April 28, 2016 at 9:00 a.m. (ET) to discuss the results with members of the investment community.
To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 93641672. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 93641672.
A live audio broadcast will be available on the investor relations section of the PRA Health Sciences website. Following the teleconference, an audio replay of the call will be available at the same website.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 12,000 employees worldwide. Since 2000, PRA has performed approximately 3,300 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 60 drugs. To learn more about PRA, please visit www.prahs.com.
INVESTOR INQUIRIES: [email protected] INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +1 919.786.8463
